Fannie Mae, Freddie Mac shares tumble after conservatorship comments
Richard Byrd, Executive Vice President and President of Interventional at Becton Dickinson & Co (NYSE:BDX), recently sold shares of the company’s stock. According to the SEC filing, Byrd sold 459 shares at a price of $230.00 each, totaling $105,570. Following this transaction, Byrd holds 6,952 shares of Becton Dickinson stock.
The sale was executed on March 18, 2025, under a pre-established Rule 10b5-1 trading plan that Byrd adopted on December 11, 2024. This type of plan allows insiders to set up a predetermined schedule for selling shares to avoid any potential accusations of insider trading. The transaction was signed by Donna Kalazdy, acting under power of attorney for Byrd. With a ’GOOD’ Financial Health Score and analyst price targets suggesting up to 18% upside potential, InvestingPro subscribers can access detailed analysis and 12 additional exclusive ProTips about BDX’s investment outlook.
In other recent news, Becton, Dickinson and Company (BD) announced plans to separate its Biosciences and Diagnostic Solutions business from the rest of the company. This strategic move is intended to enhance growth-oriented investments and value creation for shareholders. Additionally, activist investor Starboard Value has acquired a stake in BD, advocating for the sale of the life sciences division, which has reportedly resonated positively with investors. Meanwhile, BD’s shareholders have approved board nominees and ratified Ernst & Young as the independent auditor for fiscal year 2025. The company also declared a quarterly dividend of $1.04 per share and authorized additional share repurchases, reflecting its commitment to shareholder returns.
In other developments, Piper Sandler raised the price target for BD shares to $280, maintaining an Overweight rating. The analysts support a potential spin-off of the Life Sciences division, suggesting it could unlock shareholder value. These recent developments indicate significant strategic shifts and financial maneuvers aimed at optimizing BD’s market position and shareholder value.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.